Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04487444 · ClinicalTrials.gov registry record · Phase 2
Thymalfasin (Thymosin Alpha 1) to Treat COVID-19 Infection
A Phase 2 study, sponsored by Rhode Island Hospital.
- Terminated
- Registry status
- Phase 2
- Development phase
- 56
- Enrollment target
NCT04487444 is a Phase 2 study that was terminated before completion, run by Rhode Island Hospital. The registered enrollment target is 56 participants.
The verdict
NCT04487444, a Phase 2 study, was terminated before completion, sponsored by Rhode Island Hospital.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 56 participants
- Enrollment target
Study Summary
It is our hypothesis that a course of Ta1 administered to hospitalized individuals with COVID-19 infection and lymphocytopenia will improve the time to recovery (primary objective) and severity of infection (secondary objectives) compared to untreated individuals in the same hospital with comparable lymphocytopenia. After screening, hospitalized patients with COVID-19 and lymphocytopenia who meet the inclusion criteria will receive Ta1 (1.6 mg) administered subcutaneously (SC) daily for 1 week. Individuals in the control arm will be followed on the identical protocol but will not receive daily Ta1.
Interventions
- DRUG Thymalfasin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2020-09-10 |
| Est. Completion | 2023-02-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04487444
The ClinicalTrials.gov registry entry for NCT04487444 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rhode Island Hospital, which has 130 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Thymalfasin is the first listed.
NCT04487444 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04487444 about?
NCT04487444 is a clinical study titled "Thymalfasin (Thymosin Alpha 1) to Treat COVID-19 Infection". It is our hypothesis that a course of Ta1 administered to hospitalized individuals with COVID-19 infection and lymphocytopenia will improve the time to recovery (primary objective) and severity of infection (secondary objectives) compared to untreated individuals in the same hospital with comparable...
What is the current status of trial NCT04487444?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 56 participants. The study started on 2020-09-10. Estimated completion is 2023-02-03.
What interventions are being tested in trial NCT04487444?
The interventions under investigation include: Thymalfasin (DRUG).
Who is sponsoring clinical trial NCT04487444?
This trial is sponsored by Rhode Island Hospital, which has 130 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.